LOAN NUMBER 9263-ID Loan Agreement (Additional Financing for Indonesia Emergency Response to COVID-19 Program) between REPUBLIC OF INDONESIA and INTERNATIONAL BANK FOR RECONSTRUCTION AND DEVELOPMENT 2 of 23 LN 9263-ID LOAN AGREEMENT AGREEMENT dated as of the Signature Date between REPUBLIC OF INDONESIA ("Borrower") and INTERNATIONAL BANK FOR RECONSTRUCTION AND DEVELOPMENT ("Bank"). The Borrower and the Bank hereby agree as follows: (a) WHEREAS, under an agreement, dated July 6, 2020, between the Borrower and the Bank for the Indonesia Emergency Response to COVID-19 Program ("Original Loan Agreement"), the Bank agreed to provide a loan in the amount of two hundred fifty million Dollars ($250,000,000) to assist in financing the program described in Schedule I to the Original Loan Agreement ("Original Program"); (b) WHEREAS, the Borrower has requested the Bank to provide additional financial assistance in support of additional activities related to the Original Program, by extending to the Borrower an additional loan in an amount of five hundred million Dollars ($500,000,000) for this purpose; (c) (c). WHEREAS, the Borrower has also requested the Bank, acting as administrator of the Australia-World Bank Indonesia Partnership Single-Donor Trust Fund to co- finance the Program, and the Bank, acting in such capacity, has agreed to extend a grant to the Borrower from the Australia-World Bank Indonesia Partnership Single- Donor Trust Fund for such purpose in the amount of seven hundred forty thousand United States Dollars ($740,000) ("Grant"), pursuant to the Grant Agreement between the Borrower and the Bank for the Program, expected to be signed within sixty (60) days of the date of this Agreement ("Grant Agreement"); (d) WHEREAS, the AIIB and KFW (together, the "Co-financiers") intend to provide Co- financing in the amounts of five hundred million United States Dollars ($500,000,000) and two hundred million Euros (Euro 200,000,000), respectively, to the Borrower through Co-financing Agreements to assist in the financing of the Program described in Schedule 1 to this Agreement; and (e) WHEREAS, the Bank has agreed, on the basis, inter alia, of the foregoing to extend such additional financial assistance to the Borrower upon the terms and conditions set forth in this Agreement. NOW THEREFORE, the Borrower and the Bank hereby agree as follows: ARTICLE I - GENERAL CONDITIONS; DEFINITIONS 1.01 The General Conditions (as defined in the Appendix to this Agreement) apply to and form part of this Agreement. 1.02 Unless the context requires otherwise, the capitalized terms used in this Agreement have the meanings ascribed to them in the General Conditions, the Original Loan Agreement, or in this Agreement (including the Preamble and Appendix hereto). 3 of 23 LN 9263-ID ARTICLE II- LOAN 2.01. The Bank agrees to lend to the Borrower the amount of five hundred million United States Dollars ($500,000,000), as such amount may be converted from time to time through a Currency Conversion ("Loan"), to assist in financing the program described in Schedule I to this Agreement ("Program"). 2.02. The Borrower may withdraw the proceeds of the Loan in accordance with Section IV of Schedule 2 to this Agreement. All withdrawals from the Loan Account shall be deposited by the Bank into an account specified by the Borrower and acceptable to the Bank. 2.03. The Front-end Fee is one quarter of one percent (0.25%) of the Loan amount. 2.04. The Commitment Charge is one quarter of one percent (0.25%) per annum on the Unwithdrawn Loan Balance, provided that the Commitment Charge for the period beginning on the date of accrual of the Commitment Charge and ending on December 16, 2022, of accrual shall be zero percent (0)%. 2.05. The interest rate is the Reference Rate plus the Variable Spread; or such rate as may apply following a Conversion; subject to Section 3.02(e) of the General Conditions. 2.06. The Payment Dates are February I and August I in each year. 2.07. The principal amount of the Loan shall be repaid in accordance with Schedule 3 to this Agreement. ARTICLE III - PROGRAM 3.01. The Borrower declares its commitment to the objectives of the Program and the MPA Program. To this end, the Borrower, through its Ministry of Health, shall carry out the Program in accordance with the provisions of Article V of the General Conditions and Schedule 2 to this Agreement. ARTICLE IV - REMEDIES OF THE BANK 4.01. The Co-financing Deadline for the effectiveness of the Co-financing Agreements is September 30, 2021. ARTICLE V - EFFECTIVENESS; TERMINATION 5.01. The Additional Conditions of Effectiveness consist of the following: (a) The Borrower, through MOH, has developed a guideline to protect data privacy and confidentiality, in accordance with the Program Action Plan; and (b) The Borrower, through MOH, has assessed the PPE needed for COVID-19 vaccinations, in accordance with the Program Action Plan. 5.02. The Effectiveness Deadline is the date ninety (90) days after the Signature Date. 4 of 23 LN 9263-ID ARTICLE VI- REPRESENTATIVE; ADDRESSES 6.01. The Borrower's Representative is its Minister of Finance. 6.02. For purposes of Section 10.01 of the General Conditions: (a) the Borrower's address is: Directorate General of Budget Financing and Risk Management Ministry of Finance Gedung Frans Seda JI. DR. Wahidin Raya No. 1 Jakarta 10710 - Indonesia; and (b) the Borrower's Electronic Address is: Facsimile: +62-21-381-2859 E-mail: direktoratPH(&kemenkeu.go.id 6.03. For purposes of Section 10.01 of the General Conditions: (a) the Bank's address is: International Bank for Reconstruction and Development 1818 H Street, N.W. Washington, D.C. 20433 United States of America; and (b) the Bank's Electronic Address is: Telex: Facsimile: 248423(MCI) or 1-202-477-6391 E-mail: IndonesiaCMU(&worldbank.org 64145(MCI) 5 of 23 LN 9263-ID AGREED as of the Signature Date. REPUBLIC OF INDONESIA By Authorized Representative Name: LkX LMWA DM1%Or WU(,T r-INAI Title: AWD W5¶- MAWWWNT Date: 1p I A INTERNATIONAL BANK FOR RECONSTRUCTION AND DEVELOPMENT By Authorized Representative Name: KAW__6&o"4 Title: -(( ()y1 J Date: 6 of 23 LN 9263-ID SCHEDULE 1 Program Description The objective of the Program is to prevent, detect and respond to the threat posed by COVID- 19 and strengthen national systems for public health preparedness in Indonesia. The Program constitutes a phase of the MPA Program, and consists of the Original Program, as modified and described below: Part 1. Improving Hospital and Health System Readiness for COVID-19 Response and Vaccination, and Maintaining Essential Non-COVID-19 Health Services. A. Supporting health facilities designated as COVID- 19 referral hospitals under MOH supervision to have the necessary equipment, supplies, human resources and other required inputs to manage severe respiratory illness patients and critical care patients through, inter alia, procurement of medical equipment, personal protective equipment and test kits, provision of salaries and top-ups for health care providers, and provision of relevant trainings. B. Developing and implementing infection control and safety measures in healthcare settings as well as treatment protocols to manage cases at all stages. C. Updating the National Pandemic Preparedness Plan. D. Promoting use of public and private hospital capacity for free treatment of COVID- 19 patients, and improved timeliness of hospital claims payment. E. Managing unintended impact on and maintaining Essential Non-COVID Health and Nutrition Services by, inter alia, developing a deployment and mobilization plan for ongoing COVID- 19 response and mass vaccination, and ensuring that Essential Non-COVID Health and Nutrition Services are maintained. Part 2. Strengthening Public Health Laboratory, Surveillance and Supply Chain Capacity. A. Developing COVID- 19 testing capacity, backed by national guidelines for laboratories adhering to Bio Safety Level 2 or higher standards, covering sample collection, transportation, and laboratory testing procedures. B. Developing and implementing laboratory quality assurance mechanism for laboratories within MOH's network. C. (i) Strengthening the Borrower's case-surveillance system and incorporating lessons from dealing with the COVID-19 outbreak; and (ii) Developing and implementing a surveillance hotline for community-based reporting of outbreaks and new illnesses among humans and animals. 7 of 23 LN 9263-ID D. Assessing and planning actions to address gaps in supply chain and logistics for maintaining the cold chain for storage and distribution of vaccines through, inter alia, developing an action plan to address gaps in supply chain and logistics, and installing temperature monitoring devices in selected vaccine storage locations. E. (i) Improving installed capacity of quality-assured COVID-19 confirmatory testing; (ii) Introducing Rapid Antigen Testing in all Provinces; (iii) Undertaking regular genomic surveillance for variants of the COVID-19 virus; and (iv) developing and implementing a pharmacovigilance system to report adverse events in a timely manner. Part 3. Enabling Communication and Coordination for Emergency Response and Program COVID-19 Vaccine Delivery. A. Developing and establishing a communication strategy on COVID-19 (and updating it as necessary). B. Supporting the coordination with other sectors in the development and/or revision of the National Pandemic Preparedness Plan. C. (i) Upgrading the public communication and information services for COVID- 19 response and on Program COVID- 19 Vaccine deployment; and (ii) Ensuring that a communications strategy is in place. D. (i) Developing a human resource plan for Program COVID-19 Vaccine delivery; and (ii) Monitoring the training of relevant human resources engaged in Program COVID-19 Vaccine implementation, including at the subnational level. 8 of 23 LN 9263-ID SCHEDULE 2 Program Execution Section 1. Implementation Arrangements A. Program Implementation and Institutions 1. The Borrower, through MOH, shall carry out the Program in conformity with appropriate administrative, technical, financial, economic, environmental and social, and public health standards and practices, including best practices in public vaccination. 2. The institutional and other arrangements described in Section I.A and I.B.2 of Schedule 2 to the Original Loan Agreement are incorporated herein by reference in this Section with the additions set forth below, unless the context otherwise requires, and shall apply, mutatis mutandis, to the Loan, and the Borrower hereby undertakes to comply with the provisions thereof to the same extent as if such provisions had been set out in full in this Agreement, except that the reference to "Categories (1) through (10)" in Section I.B.2 of Schedule 2 to the Original Loan Agreement shall be read to refer to "Categories (1) through (9)" for the purposes of this Agreement. B. Program Action Plan Without limitation on the generality of Section I.A of this Schedule, the Borrower, through MOH, shall: 1. undertake the actions set forth in the Program Action Plan in a manner satisfactory to the Bank; 2. except as the Bank and the Borrower shall otherwise agree in writing, not assign, amend, abrogate, or waive, or permit to be assigned, amended, abrogated, or waived, the Program Action Plan, or any provision thereof; and 3. maintain policies and procedures adequate to enable it to monitor and evaluate, in accordance with guidelines acceptable to the Bank, the implementation of the Program Action Plan. 9 of 23 LN 9263-ID C. Vaccine Delivery and Distribution 1. The Borrower, through MOH, shall maintain, for the duration of the Program, Technical Guidelines for COVID- 19 vaccine delivery and distribution, in form and substance satisfactory to the Bank, which shall include: (a) rules and procedures for prioritizing intra-country vaccine allocation following principles established in the WHO Fair Allocation Framework, including an action plan setting out the timeline and steps for implementing such rules; (b) rules and procedures establishing minimum standards for vaccine management and monitoring, including medical and technical criteria, communications and outreach plan, cold chain infrastructure, and other related logistics infrastructure; (c) principles and guidance for processing and collection of Personal Data in accordance with the Program Action Plan; and (d) vaccine distribution plan, including action plan setting out timeline and steps for immunization. 2. The Borrower, through MOH, shall carry out the Program in accordance with this Agreement and the Technical Guidelines. In the event of any conflict between the provisions of the Technical Guidelines and this Agreement, the provisions of this Agreement shall prevail. D. Use of Military and Security Actors 1 . In the carrying out of Program activities, all of which are financed out of MOH's budget, the relevant sub-units of the National Armed Forces and/or the National Police under the Program shall be under the coordination of MOH. Any said activities shall be undertaken exclusively for the purposes related to the Program and strictly in accordance with the Technical Guidelines and protocols developed under the Program Action Plan, and other arrangements or protocols that the Bank may require for carrying out these activities. 2. In the carrying out of Program activities, all of which are financed out of MOH's budget, and except as the Bank may otherwise agree, the Borrower shall ensure that the ownership of any assets generated, goods procured, and works constructed by relevant sub-units of the National Armed Forces and the National Police out of the Loan proceeds shall be transferred to, or shall vest, with MOH. Section II. Excluded Activities The Borrower shall ensure that the Program excludes any activities which: A. in the opinion of the Bank, are likely to have significant adverse impacts that are sensitive, diverse, or unprecedented on the environment and/or affected people; or 10 of 23 LN 9263-ID B. involve the procurement of: (1) works, estimated to cost seventy-five million United States Dollars ($75,000,000) equivalent or more per contract; (2) goods, estimated to cost fifty million United States Dollars ($50,000,000) equivalent or more per contract; (3) non-consulting services, estimated to cost fifty million United States Dollars ($50,000,000) equivalent or more per contract; or (4) consulting services, estimated to cost twenty million United States Dollars ($20,000,000) equivalent or more per contract. Section III. Program Monitoring, Reporting and Evaluation A. The Borrower, through MOH, shall furnish to the Bank each Program Report not later than forty-five (45) days after the end of each calendar semester, covering the calendar semester. B. Except as may otherwise be explicitly required or permitted under this Agreement or as may be explicitly requested by the Bank, in sharing any information, report or document related to the activities described in Schedule 1 of this Agreement, the Borrower, through MOH, shall ensure that such information, report or document does not include Personal Data. Section IV. Withdrawal of Loan Proceeds A. General 1. Without limitation upon the provisions of Article II of the General Conditions and in accordance with the Disbursement and Financial Information Letter, the Borrower may withdraw the proceeds of the Loan to: (a) finance Program Expenditures (inclusive of Taxes), on the basis of the results ("Disbursement Linked Results" or "DLRs") achieved by the Borrower, as measured against specific indicators ("Disbursement Linked Indicators" or "DLIs") in the amount allocated against Categories (1) to (9) of the table below; all as set forth in the table in paragraph 2 of this Part A. 2. The following table specifies each category of withdrawal of the proceeds of the Loan (including the Disbursement Linked Indicators as applicable) ("Category"), the Disbursement Linked Results for each Category (as applicable), and the allocation of the amounts of the Loan to each Category: 11 of 23 LN 9263-ID Category Disbursement Linked Amount of the Formula (including Disbursement Result (as applicable) Loan Linked Indicator as Allocated applicable) (expressed in USD) (1) DLI #1: Specific DLR #1.2: The 40,000,000 DLR #1.2: additional measures to Implementation Guidelines $40,000,000 support and compensate for Health Professionals' health professionals for Support for COVID-19 Unit Price: $3,333,333 added COVID- 19 related response remain in place and per calendar month in workload and risk are the payment of benefits has 2021 that the implemented been continued in 2021. Implementation Guidelines for Health Professionals' Support for COVID- 19 response remain in place and the payment of benefits has been continued. 12 of 23 LN 9263-ID (2) DLI #3: DLR #3.3: 10,000,000 DLR #3.3: Increased capacity for In each calendar quarter of $10,000,000 patient isolation and 2021, at least 90% of hospital medical care claim payments for treating Baseline: 0 COVID- 19 patients have been received by the hospital Unit Price: within 10 business days after $2,500,000 for every the receipt of the verification calendar quarter of 2021 for such claims by MOH. that the Target is met. Target: In each calendar quarter of 2021, at least 90% of hospital claim payments for treating COVID- 19 patients have been received by the hospital within 10 business days after the receipt of the verification for such claims by MOH DLR #3.4: 60,000,000 DLR #3.4: Number of COVID-19 $60,000,000 patients with moderate to severe illnesses that receive Baseline: 0 hospitalization and have their claims paid for by the MOH, Unit Price: $300 for each on or after the date of claim paid for COVID- 19 signature of this Agreement. patients receiving free hospital treatment, up to the Target. Target: 200,000 patients 13 of 23 LN 9263-ID (3) DLI #4: Health DLR #4.2: 2000 additional 50,000,000 DLR #4.2: facilities' readiness for high care beds in existing $50,000,000 emergency response medical facilities outside Jakarta are equipped to Baseline: 2355 manage severe respiratory illnesses pursuant to the Unit Price: $25,000 per National Protocol (of which high care bed fully at least 50% are equipped equipped pursuant to with ventilators) the National Protocol, up to 2,000 new beds over and above the Baseline. (4) DLI #7: Installed DLR #7.3: Borrower has 45,000,000 DLR #7.3: capacity of quality- tested 1 person per 1000 $45,000,000 assured COVID-19 population per week confirmatory tests per day (including polymerase Unit Price: chain reaction (PCR), rapid $3,000,000 per new molecular and rapid antigen Additional Province tests) in the Additional where 1 person per Provinces. 1000 population per week is tested up to the Target. Target: 15 Additional Provinces. DLR #7.4: The Borrower 51,000,000 DLR #7.4: $51,000,000 has introduced Rapid Antigen Testing in all Baseline: 0 Provinces Provinces. Unit Price: $1,500,000 per Province that has completed the first 10,000 Rapid Antigen Testing up to the Target. Target: 34 Provinces DLR# 7.5: The Borrower is 15,000,000 DLR# 7.5: $15,000.000 undertaking regular genomic surveillance for Unit Price: $5,000,000 variants of the COVID- 19 per calendar semester in virus which at least 300 samples are tested per semester for genomic variants of the COVID- 14 of 23 LN 9263-ID 19 virus during the Target period Target: January 2021 to June 2022. (5) DLI #9: DLR #9.2: By no later than 10,000,000 DLR #9.2: Communications strategy September 30, 2021, MOH $10,000,000 on COVID- 19 based on has updated the experience and lessons- communication strategy for learned information on COVID- 19 vaccines, their rollout, eligibility, and grievance redress as well as adverse event information (6) DLI #11: Assess and DLR #11.1: 10,000,000 DLR #11.1: plan actions to address By no later than July 31, $10,000,000 gaps in supply chain and 2021, the Borrower has logistics for maintaining developed an action plan to the cold chain for storage address identified gaps in and distribution of supply chain and logistics vaccines. for maintaining the cold chain from points of entry to points of service for vaccines DLR #11.2: The Borrower 15,000,000 DLR #11.2(a): has deployed remote $15,000,000 temperature monitoring devices in vaccine storage Baseline: 0 locations (not including Jakarta) and specifically: Unit Price: (a) remote temperature $150,000 for each monitoring is installed and percentage point of functioning at the Province Identified Districts and district level; where remote temperature monitoring is installed and functioning at the Province and district level. (b) remote temperature 15,000,000 DLR #11.2(b): monitoring is installed and $15,000,000 functioning at the Puskesmas level; Baseline: 0 15 of 23 LN 9263-ID Unit Price: $150,000 for each percentage point of Identified Districts where remote temperature monitoring is installed and functioning at the Puskesmas up to the Target Target: all Identified Districts (c) end to end supply chain 15,000,000 DLR #11.2(c): management and logistics $15,000,000 information system is functional (at least for Unit Price: $7,500 per COVID- 19 vaccines) and Puskesmas where end regularly in use in 2000 to end supply chain Puskesmas as of March 31, management and 2022. logistics information system is functional (at least for COVID- 19 vaccines) and regularly in use, as of March 31, 2022. 16 of 23 LN 9263-ID (7) DLI #12: Maintaining DLR #12.1: By no later 10,000,000 DLR#12.1: unintended impact of than July 31, 2021, the $10,000,000 COVID response on Borrower has developed a essential non-COVID deployment/mobilization health services plan for ongoing COVID- 19 response and mass vaccination in a manner that preserves a share of staffing to maintain Essential Non- COVID Health and Nutrition Services. DLR #12.2: The Borrower 20,000,000 DLR #12.2: has confirmed that $20,000,000 appropriate capacity building/ training of human Baseline: No districts resources for COVID- 19 vaccine delivery has been Unit Price: $40,000 per carried out. district that has confirmed that appropriate capacity building/training of human resources for COVID- 19 vaccine delivery has been carried out up to the Target Target: 500 districts DLR #12.3: Essential Non- 69,000,000 DLR #12.3: COVID Health and $69,000,000 Nutrition Services are utilized at more than 90% Baseline: DLR #12.3 of pre-COVID utilization, Baseline (see except for the tuberculosis Appendix) program, which is utilized 82% or higher of pre- Unit Price: $3,000,000 COVID utilization per calendar quarter for each program achieving the Target Target: program is utilized at more than 90% of pre-COVID utilization, except for the tuberculosis program, which is utilized at 82% or 17 of 23 LN 9263-ID higher of pre-COVID utilization: (a) in 3 quarters between April 2021 and June 2022 in the case of the nutrition program; and (b) in each quarter between April 2021 and June 2022 for all other programs (8) DLI #13: Vaccine DLR #13.1: The Borrower 5,000,000 DLR #13.1: $5,000,000 prioritization and has developed fair and distribution is based on equitable criteria for pre-determined, fair and prioritization and objective criteria. distribution of COVID- 19 vaccines across its geographical areas through a consultative and transparent process. DLR #13.2: DLR #13.2: As of 10,000,000 $10,000,000 September 30, 2021, the prioritization, deployment and distribution of COVID- 19 vaccines has conformed to the fair and equitable criteria referred to in DLR #13.1 . DLR #13.3: DLR #13.3: As of 10,000,000 $10,000,000 December 31, 2021, the prioritization, deployment and distribution of COVID- 19 vaccines has conformed to the fair and equitable criteria referred to in DLR #13.1 18 of 23 LN 9263-ID (9) DLI #14: A DLR #14.1: The Borrower 10,000,000 DLR #14.1: pharmacovigilance has developed and $10,000,000 system is in place to implemented a report adverse events in a pharmacovigilance system timely manner to monitor any adverse events related to the COVID- 19 vaccine(s). DLR 14.2: As of September 15,000,000 DLR #14.2: 15,000,000 30, 2021, the pharmacovigilance system has been implemented and is functioning in accordance with the ITAGI Guidance, to monitor any adverse events related to the COVID-19 vaccine. DLR #14.3: DLR 14.3: As of March 31, 15,000,000 15,000,000 2022, the pharmacovigilance system has been implemented and is functioning in accordance with the ITAGI Guidance, to monitor any adverse events related to the COVID- 19 vaccine. TOTAL AMOUNT 500,000,000 B. Withdrawal Conditions; Withdrawal Period 1 . Notwithstanding the provisions of Part A of this Section, no withdrawal shall be made: (a) on the basis of DLRs achieved prior to the Signature Date, except that withdrawals up to an aggregate amount not to exceed fifty-five million five hundred thousand United States Dollars ($55,500,000) may be made for DLRs 3.3, 7.3, 7.4, and 13.1 under Categories (2), (4), and (8), respectively achieved prior to this date, but on or after November 12, 2020;and (b) for any DLR, until and unless the Borrower has furnished evidence satisfactory to the Bank that said DLR has been achieved in accordance with the provisions of the Verification Protocol. 19 of 23 LN 9263-ID 2. Notwithstanding the provisions of Part B. 1 of this Section, the Borrower may withdraw an amount not to exceed ninety-four million five hundred thousand United States Dollars ($94,500,000) as an advance; provided, however, that if the DLRs in the opinion of the Bank, are not achieved (or only partially achieved) by the Closing Date, the Borrower shall refund such advance (or portion of such advance as determined by the Bank in accordance with the provisions of paragraph (3) of this Part B) to the Bank promptly upon notice thereof by the Bank. Except as otherwise agreed with the Borrower, the Bank shall cancel the amount so refunded. Any further withdrawals requested as an advance under any Category shall be permitted only on such terms and conditions as the Bank shall specify by notice to the Borrower. 3. Notwithstanding the provisions of Part B.1(b) of this Section, if the Scalable DLRs under Categories (1) to (4), (6) or (7) have not been achieved, the Bank may, by notice to the Borrower: (a) authorize the withdrawal of such lesser amount of the unwithdrawn proceeds of the Loan then allocated to said Scalable DLR under the relevant Category which, in the opinion of the Bank, corresponds to the extent of achievement of said DLR, said lesser amount to be calculated in accordance with the Formula; (b) reallocate all or a portion of the proceeds of the Loan then allocated to said Scalable DLR to any other DLR; and/or (c) cancel all or a portion of the proceeds of the Loan then allocated to said Scalable DLR. 4. The Closing Date is December 31, 2022. 20 of 23 LN 9263-ID SCHEDULE3 Commitment-Linked Amortization Repayment Schedule The following table sets forth the Principal Payment Dates of the Loan and the percentage of the total principal amount of the Loan payable on each Principal Payment Date ("Installment Share"). Level Principal Repayments Principal Payment Date Installment Share On each February Iand August 1 Beginning August 1, 2026 6.25% through February 1, 2034 21 of 23 LN 9263-ID APPENDIX Definitions 1. "Additional Province" means each Province up to fifteen (15) Provinces, not including Jakarta, Kalimantan Selatan, Kalimantan Timur, Kalimantan Utara, Yogyakarta; and "Additional Provinces" means, collectively, all such Provinces. 2. "AIIB" means the Asian Infrastructure Investment Bank. 3. "Anti-corruption Guidelines" means, for purposes of paragraph 5 of the Appendix to the General Conditions, the Bank's "Guidelines on Preventing and Combating Fraud and Corruption in Program-for-Results Financing," dated February 1, 2012, and revised July 10, 2015. 4. "Category" means a category set forth in the table in Section IV.A.2 of Schedule 2 to this Agreement. 5. "Co-financiers" means the AIIB and KFW. 6. "Co-financing" means, for purposes of paragraph 17 of the Appendix to the General Conditions: (a) an amount of five hundred million United States Dollars ($500,000,000) to be provided by the AIIB; and (b) an amount of two hundred million Euros (EUR 200,000,000) to be provided by KFW to assist in financing the Program. 7. "Co-financing Agreement" means each of the agreements to be entered into between the Borrower and the Co-financiers providing for the Co-financing. 8. "COVAX Facility" means the COVID-19 Vaccine Global Access Facility, a mechanism through which demand and resources are pooled to support the availability of, and equitable access to, COVID-19 vaccines for all economies, and which is coordinated by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI), and the WHO. 9. "COVID-19" means the coronavirus disease caused by the 2019 novel coronavirus (SARS- CoV-2). 10. "Disbursement Linked Indicator" or "DLI" means in respect of a given Category, the indicator related to said Category as set forth in the table in Section IV.A.2 of Schedule 2 to this Agreement. 11. "Disbursement Linked Result" or "DLR" means in respect of a given Category, the result under said Category as set forth in the table in Section IV.A.2 of Schedule 2 to this Agreement, on the basis of the achievement of which, the amount of the Loan allocated to said result may be withdrawn in accordance with the provisions of said Section IV. 12. "DLR #12.3 Baseline" means the following national level baselines for each Essential Non- COVID Health and Nutrition Service: (i) antenatal care - 88.5%; (ii) facility based delivery - 88.6%; (iii) nutrition - 73.6%; (iv) routine immunization - 96.5%; (v) tuberculosis - 67%. 22 of 23 LN 9263-ID 13. "Essential Non-COVID Health and Nutrition Services" means the following services: (i) antenatal care; (ii) facility based delivery; (iii) nutrition; (iv) routine immunization; and (v) tuberculosis. 14. "Formula" means the measure for calculating disbursements against DLRs, given by the product of the Unit Price per the actual target achieved, as determined by the Bank in accordance with the table in Section IV.A.2 of Schedule 2 to this Agreement. 15. "General Conditions" means the "International Bank for Reconstruction and Development General Conditions for IBRD Financing, Program-for-Results Financing", dated December 14, 2018 (revised on August 1, 2020, December 21, 2020, and April 1, 2021). 16. "Identified Districts" means the ninety-seven (97) districts listed in the United Nations Development Program Plan dated adopted by the MOH, and as agreed between the Borrower and the Bank. 17. "ITAGI Guidance" means the guidance on pharmacovigilance issued by the Indonesia Technical Advisory Group on Immunization. 18. "KFW" means German Development Bank. 19. "MPA Program" means the multiphase programmatic approach program designed to assist IBRD and IDA-eligible countries in their efforts to prevent, detect, and respond to the threat posed by COVID- 19 and strengthen national systems for public health preparedness." 20. "National Armed Forces" means Tentara Nasional Indonesia, the national armed forces of the Borrower, or any successor(s) thereto. 21. "National Police" means Kepolisian Negara Republik Indonesia, the national police forces of the Borrower, or any successor(s) thereto. 22. "OneData System" means the Borrower's system for the administration of COVID-19 vaccines. 23. "Program COVID-19 Vaccine" means a vaccine for the prevention of COVID-19, authorized by the Borrower's national regulatory authority for distribution, marketing and administration with the territory of the Borrower, and deployed under the Program, that: (a) has received regular or emergency licensure or authorization from at least one of the Stringent Regulatory Authorities identified by WHO for vaccines procured and/or supplied under the COVAX Facility, as may be amended from time to time by WHO; (b) has received the WHO Prequalification or WHO Emergency Use Listing; or (c) has met such other criteria as may be agreed in writing between the Borrower and the Bank; and "Program COVID-19 Vaccines" means the plural thereof. 24. "Province" means a province in the Borrower's territory; and "Provinces" means the plural thereof. 23 of 23 LN 9263-ID 25. "Puskesmas" means all community health centers that are identified as administering COVID- 19 vaccinations as per the OneData System. 26. "Rapid Antigen Testing" means a diagnostic method to detect SARS-CoV-2 using nucleic acid amplification tests, as defined and regulated by MOH Regulation 446/2021. 27. "Scalable DLR" means any of the following DLRs: 1.2, 3.3, 3.4, 4.1, 7.3, 7.4, 7.5, 11.2, 12.2, or 12.3. 28. "Signature Date" means the later of the two dates on which the Borrower and the Bank signed this Agreement and such definition applies to all references to "the date of the Loan Agreement" in the General Conditions. 29. "Stringent Regulatory Authority" means a National Regulatory Authority ("NRA") that is classified by WHO as a Stringent Regulatory Authority. 30. "Technical Guidelines" means the Borrower's Technical Guidelines For The Implementation Of Vaccination To Control Corona Virus Disease (COVID- 19) Pandemic dated May 7, 2021, referred to in Section I.C of Schedule 2 to this Agreement. 31. "Unit Price" means, in respect of any DLR, the amount set forth in the fourth column of the table in Section IV.A.2 of Schedule 2 to this Agreement. 32. "Verification Protocol" means the protocol setting forth the verification arrangements to be observed in order to ascertain the achievement of DLRs, as agreed with the Bank, dated May 24, 2021, as the same may be amended from time to time with the agreement of the Bank. 33. "WHO" means the World Health Organization. 34. "WHO Emergency Use Listing" means a risk-based procedure for assessing and listing by WHO of unlicensed vaccines, therapeutics, and in vitro diagnostics with the aim of expediting the availability of these products to people affected by a declared public health emergency. 35. "WHO Fair Allocation Framework" means the rules which govern the allocation of vaccines to participants in the COVAX Facility, as developed by WHO, subject to periodic review by the COVAX Facility. 36. "WHO Prequalification" means a service provided by WHO to assess the quality, safety, and efficacy of medical products for priority diseases, and which are intended for United Nations and international procurement to developing countries.